Scatter factor protects tumor cells against apoptosis caused by TRAIL

Anti-Cancer Drugs

Volumn 21, Issue 1, 2010, Pages 10-24

  Fan, Saijun ^a   Meng, Qinghui ^a   Laterra, John J ^c   Rosen, Eliot M ^a,b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; C Met; Death receptors; DR4; DR5; Hepatocyte growth factor; PHA665752; Scatter factor; TRAIL

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; BAY 11 7092; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLOOXYGENASE 2; DOXORUBICIN; FLICE INHIBITORY PROTEIN; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; LUCIFERASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRYPAN BLUE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN STABILITY; RNA INTERFERENCE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOGS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FLOW CYTOMETRY; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOPRECIPITATION; INDOLES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-MET; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; SULFONES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC;

EID: 74349115256     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832afc3b     Document Type: Article

References (53)

1. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994; 127:1783-1787. Review.
2. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22:309-325. Review.
3. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802-804.
4. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, et al. Mechanism of met oncogene activation. Cell 1986; 45:895-904.
5. Rosen EM, Goldberg ID. Regulation of angiogenesis by scatter factor. EXS 1997; 79:193-208. Review.
6. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005; 15:49-51. Review.
7. Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, et al. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol 2005; 20:1339-1349. Review. (Pubitemid 41489177)
8. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994; 54:1630-1633.
9. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63:1101-1105.
10. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, Landreneau RJ. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997; 57:433-439.
11. Tsukinoki K, Yasuda M, Mori Y, Asano S, Naito H, Ota Y, et al. Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma. Oncol Rep 2004; 12:1017-1021.
12. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004; 91:31-67. Review.
13. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncol 2005; 7:436-451. Review.
14. Joseph A,Weiss GH, Jin L, Fuchs A, Chowdhury S, O'Shaugnessy P, et al. Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst 1995; 87:372-377.
15. Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med 2004; 4:855-868. Review.
16. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63:6272-6281.
17. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, Comoglio PM, et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 2002; 62:7025-7030.
18. Fan S, Meng Q, Laterra JJ, Rosen EM. Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage. Oncogene 2007; 26:4774-4796.
19. Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, et al. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005; 24:1749-1766.
20. Xu J, Gao M, Fan S, Meng Q, Goldberg ID, Abounader R, et al. Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells. Oncogene 2007; 26:2925-2938.
21. Ma Y, Yuan RQ, Fan S, Hu C, Goldberg ID, Laterra JJ, et al. Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum. Anticancer Drugs 2006; 17:733-751.
22. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang C-P, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-682.
23. Baetu TM, Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev 2002; 13:199-207. Review.
24. Degli-Esposti MA, DougallWC, Smolak PJ,Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappa-B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7:813-820.
25. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Update 2008; 1:17-24. Review.
26. Malhi H, Gores GJ. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 2006; 5:7333-7335.
27. Cong LN, Chen H, Li Y, Zhou L, McGibbon MA, Taylor SI, et al. Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol 1997; 11:1881-1890.
28. Reddy S, Mazzu D, Mahan D, Shalloway D. Sequence and functional differences between Schmidt-Ruppin D and Schmidt-Ruppin A strains of pp60v-src. J Virol 1990; 64:3545-3550.
29. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, et al. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol 1995; 15:2809-2818.
30. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601.
31. Braeuer SJ, Büneker C, Mohr A, Zwacka RM. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res 2006; 4:715-728.
32. Lippa MS, Strockbine LD, Le TT, Branstetter DG, Strathdee CA, Holland PM. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis 2007; 12:1465-1478.
33. Fan S, Ma YX, Wang JA, Yuan RQ, Meng Q, Cao Y, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene 2000; 19:2212-2223.
34. Fan S, Ma YX, Gao M, Yuan RQ, Meng Q, Goldberg ID, et al. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol Cell Biol 2001; 21:4968-4984.
35. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997; 272:21096-21103.
36. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63:7345-7355.
37. Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, et al. Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005; 11:8122-8130.
38. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002; 62:4903-4908.
39. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96:1769-1780.
40. Martin S, Phillips DC, Szekely-Szucs K, Elghazi L, Desmots F, Houghton JA. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 2005; 65:11447-11458.
41. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 2006; 72:1161-1179. Review.
42. Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D, et al. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB: p52 dimers. EMBO J 2004; 23: 4202-4210.
43. Jeffers M, Taylor GA,Weidner KM, Omura S, VandeWoude GF. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol Cell Biol 1997; 17:799-808. (Pubitemid 27044379)
44. Hammond DE, Carter S, McCullough J, Urbé S, Vande Woude G, Clague MJ. Endosomal dynamics of Met determine signaling output. Mol Biol Cell 2003; 14:1346-1354.
45. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available c-Met kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 2008; 36:1267-1274.
46. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67:4408-4417.
47. Koon EC, Ma PC, Salgia R,Welch WR, Christensen JG, Berkowitz RS, et al. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 2007; 18:976-984.
48. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003; 63:5462-5469.
49. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-6152.
50. Kim KJ,Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, et al. Systemic antihepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006; 12:1292-1298.
51. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66:1721-1729.
52. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102:303-310.
53. Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 2002; 53:286-299.